Overview

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Treatments:
Capecitabine
Carboplatin
Cisplatin
Fluorouracil
Gemcitabine
Liver Extracts